TiilT - Preclinical development of a 3rd-generation interleukin-2 targeted to inflammatory sites

    Project: Research

    Project Details

    AcronymTiilT
    StatusActive
    Effective start/end date1/06/2023 → 31/05/2028

    Collaborative partners

    • King's College London
    • University of Lübeck
    • INSERM
    • Università degli Studi di Trieste
    • ILTOO Pharma
    • French Alternative Energies and Atomic Energy Commission
    • Medical University of Vienna
    • University of Paris IV - Paris-Sorbonne University (lead)

    Funding

    • TSB Technology Strategy Board: £338,776.34